Subsequent studies in BCR-ABL-expressing cells also predicted that continuous suppression of BCR-ABL would be necessary for clinical benefit in CML [8], and therefore, although data generated in immortalized hematopoietic cell lines should always be treated with caution, their utility should not be underestimated. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.